Loading stock data…
$36.54-1.72 (-4.50%)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
UroGen Pharma Ltd. in the Healthcare sector is trading at $36.54 with a market capitalization of $2.3B. Wall Street consensus targets $60.00 (8 analysts), implying a +64.2% move over the next 12 months. The stock is currently 28% below its 52-week high of $50.81, remaining 19.6% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $72.46M↑ | $50.96M↑ | $37.84M↑ | $27.48M↑ | $24.21M |
| Gross Profit | $65.88M↑ | $46.82M↑ | $34.55M↑ | $24.20M↑ | $20.66M |
| Operating Income | $111,000↑ | -$20.26M↓ | -$19.11M↑ | -$27.39M↑ | -$41.45M |
| Net Income | -$14.35M↑ | -$23.57M↑ | -$26.36M↑ | -$33.35M↑ | -$49.94M |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technolog...